Biomarkers and Preclinical Models for Adult T-Cell Leukemia-Lymphoma Treatment

Ratner, Lee

doi:10.3389/fmicb.2019.02109

Cited by 1 publication

(1 citation statement)

References 75 publications

(90 reference statements)

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Antibody discovery remains the biggest challenge because selected antibodies are required to recognize cancer cell molecular targets, such as signaling receptors [ 7 , 8 ]. For the diagnosis and treatment of cancers, antibodies engineered from the variable domain of heavy-chain (VHH) antibody have gained significant attention because it contains several outstanding properties that favor novel biologics.…”

Section: Introductionmentioning

confidence: 99%

A Novel Strategy for Screening Tumor-Specific Variable Domain of Heavy-Chain Antibodies

Rafique

Hichiwa

Jatnika

et al. 2023

IJMS

View full text Add to dashboard Cite

The properties of the variable domain of heavy-chain (VHH) antibodies are particularly relevant in cancer therapy. To isolate tumor cell-specific VHH antibodies, VHH phage libraries were constructed from multiple tumor cells. After enriching the libraries against particular tumor cell lines, a next-generation sequencer was used to screen the pooled phages of each library for potential antibody candidates. Based on high amplification folds, 50 sequences from each library were used to construct phylogenetic trees. Several clusters with identical CDR3 were observed. Groups X, Y, and Z were assigned as common sequences among the different trees. These identical groups over the trees were considered to be cross-reactive antibodies. To obtain monoclonal antibodies, we assembled 200 sequences (top 50 sequences from each library) and rebuilt a combined molecular phylogenetic tree. Groups were categorized as A–G. For each group, we constructed a phagemid and determined its binding specificity with tumor cells. The phage-binding results were consistent with the phylogenetic tree-generated groups, which indicated particular tumor-specific clusters; identical groups showed cross-reactivity. The strategy used in the current study is effective for screening and isolating monoclonal antibodies. Specific antibodies can be identified, even when the target markers of cancer cells are unknown.

show abstract

Section: Introductionmentioning

confidence: 99%